Amgen Inc
AMGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000318154
In the last 90 days, Amgen Inc insiders filed 0 open-market purchases and 3 sales; 3,169 institutions reported holding it in 13F filings for Q2 2026, worth $161.7B in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Amgen Inc changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Of which not filed for Q3 2025 | Q3 2025 | Change |
|---|---|---|---|---|
| Holders | 2,860 | 44 | 2,828 | +12 |
| Shares | 432.2M | 6.64M | 423.1M | −2.40M (−0.6%) |
| Value | $120.5B | $1.86B | $119.4B | +$668.5M (+0.6%) |
44 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (144)
Institutions that held Amgen Inc at the end of Q3 2025 but not at the end of Q2 2025.
Showing the largest 100 of 144 by value.
Sold out (132)
Institutions that held Amgen Inc at the end of Q2 2025 and filed for Q3 2025 without it.
Showing the largest 100 of 132 by value.
Not filed for Q3 2025 yet (44)
Institutions that held Amgen Inc at the end of Q2 2025 and haven't filed a 13F for Q3 2025. Not filing isn't selling, so they aren't counted as sold out.